Navigation Links
Studies on Urgent(R) PC to be Presented at the 2008 Society of Urologic Nurses and Associates Annual Symposium
Date:2/11/2008

MINNEAPOLIS, Feb. 11 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunction, announced today that the Urgent(R) PC Neuromodulation System, its proprietary, minimally invasive nerve stimulation device, designed for office-based treatment of overactive bladder (OAB) symptoms, will be featured in three presentations at the Society of Urologic Nurses and Associates (SUNA) Annual Symposium. SUNA will be held at the Marriott Waterside Hotel and Marina in Tampa, Florida from Thursday, February 28, through Sunday, March 2. These retrospective and observational studies examined the use of Urgent(R) PC Neuromodulation System to deliver the percutaneous tibial nerve stimulation (PTNS) for the treatment of OAB symptoms of urinary urgency, urinary frequency, and urge incontinence. The Company will present a summary of these presentations on Monday, March 3 before the market opens. The schedule for the oral presentation and poster-discussion sessions is as follows:

-- Leslie Wooldridge, MSN, RNCS, GNP.F, BCIA-PMBD, Director of the Bladder

Control Clinic, Hackley Health at the Lakes Women's Center, Muskegon,

Michigan, "Percutaneous Tibial Nerve Stimulation: Revival of an Old

Technology for Treatment of Overactive Bladder," Sunday, March 2, at 8

am, oral presentation

-- Vanessa K. Hardy, WHNP, APN, MSN, Nurse Practitioner, Urogynecology,

Vanderbilt University Medical Center, Nashville, Tennessee,

"Percutaneous Tibial Nerve Stimulator: A Viable Option for Urgency,

Frequency, and Urge Incontinence," Friday, February 29 through

Saturday, March 1, poster presentation

-- Lesbia Candelaria, RN, Winter Park Urology Associates, Orlando,

Florida, "Percutaneous Tibial Nerve Stimulation (PTNS) Treatment for

Overactive Bladder (OAB) P
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Pathology Reports Good for Breast Cancer Studies
2. Best Practice Database: Complimentary Excerpt of Three Sales Force Excellence Studies
3. Policy Studies Inc. (PSI) Awarded Contract to Operate the Commonwealth of Kentuckys New Hire Reporting Program
4. Akela Pharma receives letter from the FDA regarding its pre-clinical toxicology studies for Fentanyl TAIFUN(R)
5. California Institute of Integral Studies Launches Groundbreaking Community Mental Health Program
6. Stem cell therapy studies for stroke, cerebral palsy prepare for clinical trials
7. UK Center for Tobacco Control Studies to be based in Nottingham
8. Cell division studies hint at future cancer therapy
9. Freeze-dried tendon implants prove effective in early studies
10. Rockefeller Universitys Center for Clinical and Translational Science funds pilot studies
11. ASPS Studies Re-Evaluate Psychological Benefits and Health Concerns of Silicone Breast Implants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... Liver is the largest organ inside the human ... body in barring itself from poisons, helps in digestion of ... plays many important functions such as protein production, blood clotting ... illnesses can affect the liver, an organ the size of ... right side of the abdomen, reducing its capabilities to perform ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Currently, ... more effective treatments for Alzheimer's disease (AD), which ... also exist regarding the diagnosis of the disease, ... lack of appropriate diagnostic tests. In 2014, ... the greatest breakthroughs in the medicine world, there ...
(Date:9/1/2014)... An operating theatre or operating room is ... operations. An operating room comprises a myriad of specially-designed ... lights, imaging displays as well as integration systems for ... Research, a U.S.-based market research firm, the operating room ... by 2019. , According to this report, the ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 More than ... added to a federal litigation that continues to progress ... Bernstein Liebhard LLP reports. , A federal Case ... filed over the widely-used cholesterol medication by plaintiffs who ... According to claims, Pfizer Inc. failed to adequately warn ...
(Date:9/1/2014)... "Women struggle with weight gain typically ... begin as early as 15, if not earlier. ... ups and downs of hormone related weight gain. ... sizes seems to rage against the hidden and ever-present ... her 40's begin to face menopause and related changes, ...
Breaking Medicine News(10 mins):Health News:Global Liver Diseases and Therapies Market- The Key Basics by Transparency Market Research 2Health News:Global Liver Diseases and Therapies Market- The Key Basics by Transparency Market Research 3Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 3Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 2Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 3
... took place even in prehistoric times. , , FRIDAY, June 13 ... based on the findings of a prehistoric mass grave in ... evidence from 34 skeletons dating back to around 5000 B.C. ... over the need for female companionship. , While adult ...
... June 13 EntreMed, Inc.,(Nasdaq: ENMD ... the treatment of cancer and inflammatory diseases,announced ... Chief Executive Officer,will present a Company overview ... Organization 2008 Annual International Convention,being held June ...
... trachomatis, the most ... Calif., June 13 Roche announced today that,its new ... Mark,certification, allowing it to be sold for clinical use ... target approach to help ensure,reliability of test results even ...
... terrorist attacks of September 11, 2001, had lasting psychological ... World Trade Center Health Registry, show that one in ... (PTSD) two to three years after the attacks. The ... three times the usual rate in the years following ...
... for Prevention, Mental,Health and Low-Income Programs, Boosted Quality ... Today a minority of,the U.S. Senate blocked critical ... million Americans who depend on it. The Medicare,Improvements ... improved,Medicare,s prevention, mental health, and low-income programs and,instituted ...
... Synovics,Pharmaceuticals, Inc., (OTC Bulletin Board: SYVC) a ... 2008, it formalized,a strategic partnership with Maneesh Pharmaceuticals, ... ("JV"). The JV between the,companies is intended to ... have access,to assets of Maneesh including personnel, drug ...
Cached Medicine News:Health News:Pursuit of Females Dates Way, Way Back 2Health News:EntreMed to Present at the BIO 2008 Annual International Convention 2Health News:New Roche Chlamydia Test Approved for Use in European Union 2Health News:New Roche Chlamydia Test Approved for Use in European Union 3Health News:1 in 8 Lower Manhattan residents had signs of PTSD 2 to 3 years after 9/11 2Health News:AARP NY Key Vote News Alert: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 2Health News:AARP NY Key Vote News Alert: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 3Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 2Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 3Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 4Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 5Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 6
(Date:8/29/2014)... According to the new ... (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User (Research, ... Synthesis, NGS, DNA, RNAi) - Global Forecast to ... Market is expected to reach $1,712.1 Million by ... a CAGR of 9.8% from 2014 to 2019.. ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Global Multiple Sclerosis Drugs Market 2014-2018" report ... a chronic, inflammatory medical condition that results in demyelination, ... because of an abnormal response by the immune system, ... It is a potentially debilitating disease in which the ...
(Date:8/29/2014)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the Company") today ... financial statements.  The Company recently changed its fiscal year ... application to list its common stock on a national ... DelMar,s financial statements as filed with the United States ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... Jan. 5, 2011 Although smoking is an expensive habit, ... quit smoking can seem like expensive purchases as well.  The ... try to do it "cold turkey" – the most popular ... to relapse.   The use of store brand ...
... Avaxia Biologics, Inc., a privately-held biotech company developing ... to the gastrointestinal tract, announced today that it ... of inflammatory bowel disease (IBD). Avaxia,s orally administered ... three different animal models and showed superior efficacy ...
Cached Medicine Technology:Resolved to Quit Smoking This Year? 2Resolved to Quit Smoking This Year? 3Avaxia Biologics, Inc. to Present Key Pre-Clinical Inflammatory Bowel Disease Remission Data at Biotech Showcase 2011 2
Binocular indirect ophthalmic lenses. Median field diagnosis & treatment....
Binocular indirect ophthalmic lenses. Ultra-High resolutions viewing of posterior pole....
... Volk's super series ... lenses. General retinal ... unprecedented fundus diagnostic ... maximum potential field ...
Volk indirect lenses. Standard BIO examinations....
Medicine Products: